Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference

 Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th
                         Annual Healthcare Conference

-- Arena to Also Present at the Leerink Swann 6th Annual POLARxPRESS Bus Tour

PR Newswire

SAN DIEGO, Nov. 21, 2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:
ARNA) announced  today that the company is scheduled to present at the Piper
Jaffray 24^th Annual Healthcare Conference on Wednesday, November 28, 2012, at
8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at The New York Palace Hotel
in New York City. Jack Lief, Arena's President and Chief Executive Officer,
and Craig M. Audet, Arena's Senior Vice President, Operations and Head of
Global Regulatory Affairs, are scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor
relations section of Arena's website at A replay of the
presentation will be available for 30 days following the event. Please connect
to Arena's website several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.

Arena also announced today that it is scheduled to present at the Leerink
Swann 6^th Annual POLARxPRESS Bus Tour on November 28, 2012, in New York City.
This presentation will not be webcast.

About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing and commercializing novel drugs for weight management,
cardiovascular disease, inflammation and other disorders. BELVIQ^® (lorcaserin
HCl), Arena's internally discovered drug, was approved by the US Food and Drug
Administration in June 2012, and is under review for regulatory approval in
additional jurisdictions. Arena's US operations are located in San Diego,
California, and its operations outside of the United States, including its
commercial manufacturing facility, are located in Zofingen, Switzerland. For
more information about Arena, please visit

Arena Pharmaceuticals^® and Arena^® are registered service marks of Arena
Pharmaceuticals, Inc. BELVIQ^® is a registered trademark of Arena
Pharmaceuticals GmbH.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that
involve a number of risks and uncertainties. Such forward-looking statements
include statements about the regulatory review of BELVIQ; and Arena's focus,
goals, strategy, research and development programs, and ability to discover
and develop compounds and commercialize drugs. For such statements, Arena
claims the protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's expectations.
Factors that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the following:
risks related to commercializing drugs, including regulatory, manufacturing
and supply issues and the pace of market acceptance; cash and revenues
generated from BELVIQ, including the impact of competition; the timing and
outcome of regulatory review is uncertain; government and commercial
reimbursement and pricing decisions; risks related to relying on collaborative
arrangements; the timing and receipt of payments and fees, if any, from
collaborators; the entry into or modification or termination of collaborative
arrangements; unexpected or unfavorable new data; nonclinical and clinical
data is voluminous and detailed, and regulatory agencies may interpret or
weigh the importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or after
approval; data and other information related to any of Arena's research and
development may not meet safety, efficacy or other regulatory requirements or
otherwise be sufficient for further research and development, regulatory
review or approval or continued marketing; Arena's ability to obtain and
defend patents; the timing, success and cost of Arena's research and
development programs; results of clinical trials and other studies are subject
to different interpretations and may not be predictive of future results;
clinical trials and other studies may not proceed at the time or in the manner
expected or at all; having adequate funds; and satisfactory resolution of
litigation or other disagreements with others. Additional factors that could
cause actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.

Contact: Arena Pharmaceuticals, Inc.       Media Contact: Russo Partners
Cindy McGee, Vice President,               David Schull, President
Investor Relations & Alliance Management                     858.717.2310
858.453.7200, ext. 1479

SOURCE Arena Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.